QUANTUM HEALTHCARE LIMITED
(Company Registration No. 202218645W)
(Incorporated in Singapore)

RESPONSE TO QUERY FROM SINGAPORE EXCHANGE SECURITIES TRADING LIMITED ("SGX-ST") IN RELATION TO INDEPENDENT DIRECTOR CHONG ENG WEE

The Board of Directors of the Quantum Healthcare Limited (the "**Company**" and together with its subsidiaries, the "**Group**") refers to the query from the Singapore Exchange Securities Trading Limited ("**SGX-ST**") on 11 August 2026 in relation to Independent Director Chong Eng Wee ("**Mr Chong**"). The Company sets out below its response to the said query.

SGX Query:

We note that Chong Eng Wee is appointed as a Director of the Company. He was also recently appointed to the Board of Unusual Limited ("**UL**") on 3 August 2026 and is currently a director of nine listed companies in total. Other than the above, he has principal commitments in respect of five non listed companies.

In response to SGX RegCo's compliance query to UL as announced on 7 August 2026, UL represented among others that Mr Chong shall retire as the Non-Executive and Independent Chairman of a SGX-listed company at its next annual general meeting ("**AGM**"), and he also does not intend to stand for re-election as a Non-Executive and Independent Director of another SGX-listed company at its next AGM.

(a) Provision 4.5 of the Code of Corporate Governance requires the Company's Nominating Committee ("**NC**") to determine if a director is able to and has been adequately carrying out his or her duties as a director of the company. Where a director holds a significant number of directorships and principal commitments, the NC and the Board must provide a reasoned assessment of the ability of the director to diligently discharge his or her duties.

Please provide the detailed bases for the Board and NC's assessment on whether Mr Chong will be able to carry out his duties as a Director of the Company effectively, considering his other competing commitments (including multiple board representations).

(b) Please clarify whether Mr Chong has informed the Board that he intends to retire or not stand for re-election as a Director of the Company at the next AGM.

Company's Response to Query (a):

In assessing Mr. Chong's ability to discharge his duties effectively notwithstanding his other principal commitments and board appointments, the Board and the NC (with Mr. Chong abstaining from deliberations) understand from Mr. Chong and/or took into account, among others, the following:

(i) Mr Chong is admitted to practise in multiple jurisdictions and possesses approximately 20 years of legal experience in capital markets, mergers and acquisitions, private equity and regulatory compliance matters. His familiarity with the SGX-ST Listing Rules and applicable Singapore laws, together with his experience of having advised and/or been involved with transactions and/or companies operating in the medical and/or dental industries equip him with a good understanding of the business, the key issues and/or risks associated with these industries. The Board and/or management of the Company find it beneficial and helpful to be able to tap on Mr. Chong's knowledge and experience during strategy discussions pertaining to the potential restructuring of the Group's existing or legacy businesses;

(ii) The NC and the Board further note Mr. Chong's role as an independent director and/or chairman of numerous other SGX-ST and Hong Kong-listed companies. This allows Mr. Chong to have a wide network of business contacts (which the Group can utilise in connection with its future corporate plans) and makes him well-placed to contribute towards the Company's corporate governance, risk management and regulatory compliance needs, and to exercise board oversight, enabling him to contribute effectively to the Company;

(iii) other than his directorships at listed companies, Mr Chong's principal commitments at non-listed companies primarily comprise his legal practice as Managing Director of Chevalier Law LLC ("**CLL**") and as Partner of Nixon Peabody CWL ("**NPCWL**") which constitute 2 out of his directorships at non-listed companies. His remaining 3 directorships at non-listed companies pertain to him acting in a local nominee director capacity and/or being a director for a dormant company;

(iv) Mr Chong's legal practice at CLL and NPCWL primarily involve business development, origination and/or management duties, and he is supported by other lawyers at CLL and NPCWL who are responsible for execution of client matters. The NC and the Board understand that this allows Mr Chong to plan his professional commitments for CLL and/or NPCWL around Board and Board committee meetings of the Company which are typically scheduled in advance;

(v) Mr Chong's track record of full attendance at Board and Board committee meetings of the Company and his adequate preparation for such meetings to date demonstrate his continued ability to devote sufficient time to the Company's affairs despite his other principal commitments; and

(vi) The NC and the Board further understand that Mr. Chong shall retire as the Non-Executive and Independent Chairman of a SGX-ST Catalist listed company at its next Annual General Meeting (in view of the 9 years' tenure rule) and also intends to not stand for re-election as an independent non-executive director of another SGX-ST Catalist listed company at its next Annual General Meeting. The NC and Board believe that these will provide him with additional bandwidth to devote extra time and attention to the Company's affairs, if required.

Having considered the foregoing, including the nature and extent of Mr Chong's principal commitments, his professional qualifications and experience, his familiarity with key issues and/or risks prevalent in the medical and/or dental services business, the Board and the NC are satisfied that Mr Chong is able to devote sufficient time and attention to the Company's affairs and to discharge his duties and responsibilities effectively as a Director, notwithstanding his other principal commitments and board appointments.

Company's Response to Query (b):

Mr. Chong has not informed the Board that he intends to retire or not stand for re-election as a Director of the Company at the next AGM.

By Order of the Board

QUANTUM HEALTHCARE LIMITED

Gian Siong Lin Jimmy
Executive Chairman and Chief Executive Officer
13 August 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.